SLT Holdings LLC Takes $66,000 Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

SLT Holdings LLC acquired a new stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) in the fourth quarter, Holdings Channel.com reports. The firm acquired 31,000 shares of the company’s stock, valued at approximately $66,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its position in shares of Black Diamond Therapeutics by 6.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 109,224 shares of the company’s stock worth $475,000 after purchasing an additional 7,021 shares in the last quarter. Rhumbline Advisers increased its position in shares of Black Diamond Therapeutics by 14.9% during the fourth quarter. Rhumbline Advisers now owns 56,135 shares of the company’s stock worth $120,000 after purchasing an additional 7,290 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Black Diamond Therapeutics during the third quarter worth approximately $49,000. MetLife Investment Management LLC increased its position in shares of Black Diamond Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 22,286 shares of the company’s stock worth $97,000 after purchasing an additional 12,557 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Black Diamond Therapeutics during the third quarter worth approximately $56,000. 95.47% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on BDTX. Stifel Nicolaus dropped their price target on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. Wedbush reissued an “outperform” rating and set a $11.00 price objective (down previously from $16.00) on shares of Black Diamond Therapeutics in a research note on Friday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $14.40.

Black Diamond Therapeutics Stock Performance

NASDAQ BDTX opened at $1.88 on Friday. The stock’s fifty day moving average is $2.23 and its two-hundred day moving average is $3.18. The firm has a market capitalization of $106.38 million, a P/E ratio of -1.41 and a beta of 2.52. Black Diamond Therapeutics, Inc. has a fifty-two week low of $1.77 and a fifty-two week high of $7.66.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. As a group, sell-side analysts forecast that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current year.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.